First Parkinson’s Disease Patient Treated with ALX-001 in Allyx Therapeutics, DCRI Study
Allyx Therapeutics has announced that the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics and potential therapeutic response in patients with Parkinson’s disease. ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy. Allyx Therapeutics is a clinical-stage biotechnology company working to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases.
Wearable Heart Monitor Increases Diagnosis of Irregular Heart Rhythm
Wearable, long-term continuous heart monitors helped identify 52% more cases of atrial fibrillation compared to usual care, but that did not lead to a reduction in hospitalizations due to stroke, according to a study led by the Duke Clinical Research Institute.
i-Cubed Launches Innovation Spotlight Series with Early-Stage Startup Alleviate Health
A new event series hosted by i-Cubed promises to forge connections and accelerate promising startups to expedite breakthroughs and improve efficiencies in clinical res
DCRI Unveils New Imaging and Translational Biomarker Evidence in Pulmonary Fibrosis and Lung Disease from the IPF-PRO/ILD-PRO Registry
New evidence and results from eight studies based on data from the IPF-PRO/ILD-PRO Registry was shared by the Duke Clinical Research Institute (DCRI) and its collaborators at the American Tho
Study Confirms No Benefit to Taking Montelukast for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit in taking montelukast at a dosa
3 DCRI Faculty Receive Duke School of Medicine Awards
Three Duke Clinical Research Institute faculty members were honored by the Duke School of Medicine during the school’s annual faculty awards ceremony on Tuesday, May 14.
DCRI Collaborates with Biotechnology Partners to Promote Innovation in Precision Health
The Precision Health Alliance, a new consortium co-founded by the Duke Clinical Research Institute (DCRI), Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Verve Therapeutics, launched today to promote innovation in precision health and medicine. Additional academic and industry collaborators are expected to join the alliance in the future.
Study Shows Alarming Rise in Heart Failure Deaths, Especially Among Younger Adults
After decades of decline, heart failure mortality is climbing, with a dramatic rise in heart failure deaths among younger adults. The number of people dying from heart failure in the United States went down steadily from 1999 to 2009. However, progress made in treating heart failure began unraveling from 2009 to 2012 when heart failure-related mortality rates plateaued, according to a study led by Duke University School of Medicine.
Drug Development for Major Chronic Health Conditions–Aligning With Growing Public Health Needs
Read insights from a recent DCRI Think Tanks where experts discussed the current state of drug development for chronic health conditions, identified key barriers, and formulated six action items to accelerate drug development.
New Partnership for Metabolic Platform to Accelerate Weight Loss Research and Treatment
The Duke Clinical Research Institute (DCRI) and the Duke Margolis Institute for Health Policy are working to establish a platform for characterizing obesity management patterns and treatment responses while addressing barriers to clinical trials integrated into patients’ point-of-care experience. This new initiative — known as the Platform for Evidence GeneraTion in Cardiometabolic HeaLth (PETAL) — is a collaborative effort with Eli Lilly and Company to better understand the landscape of weight loss research and treatment.